Leerink Partners analyst David Risinger has maintained their bullish stance on XOMA stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Risinger has given his Buy rating due to a combination of factors including Xoma’s strategic acquisition activities and innovative financial strategies. The company has recently announced its acquisition of Mural Oncology, which is part of its broader strategy of engaging in ‘liquidation-as-a-service’ transactions. This approach has been demonstrated in previous deals with Turnstone and HilleVax, potentially bringing in low to mid-single digit millions of dollars per transaction.
Furthermore, Xoma’s acquisition of LAVA Therapeutics to secure royalty rights in partnerships with major players like JNJ and PFE showcases its ability to generate capital and secure future revenue streams through unconventional means. These strategic moves highlight Xoma’s proactive approach to growth and revenue diversification, underpinning Risinger’s confidence in maintaining an Outperform rating for the stock.
According to TipRanks, Risinger is a 5-star analyst with an average return of 9.3% and a 56.71% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Regeneron, Eli Lilly & Co, and Amgen.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $104.00 price target.